KV's Makena delivers $1,500 sticker shock to docs

KV Pharmaceutical isn't making any friends with the $1,500-per-dose price tag on its new drug for preventing premature births. Just approved by the FDA last month, KV's Makena is a commercial form of the low-cost progesterone treatments used by women for years.

Those progesterone treatments, made by compounding pharmacies, weren't FDA approved. And the FDA has been on something of a crusade to sweep aside unapproved drugs. The medical community had supported KV's quest to win the FDA nod for Makena, the Associated Press reports, because the quality of treatment would be more consistent, and it would be easier to obtain.

Physicians hadn't expected Makena to cost so much, however. And now that Makena has the FDA's blessing, the pharmacies that formulated weekly progesterone shots for women at $10 to $20 each must stop doing so, the Los Angeles Times reports. And that's making doctors angry. Insurers aren't likely to be happy either, given they'll be reimbursing at a much higher rate for a similar treatment.

KV tells the LA Times that it's launching a patient assistance program to make sure all women who need the drug can get it. Now that it has FDA exclusivity, KV will certainly be the go-to source.

- see the LA Times piece
- get the coverage from AP

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.